A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
HS-10381 is a small molecular, oral potent, SHP2 inhibitor. The first-in-human trial is
conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to
evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10381 in
Patients With Advanced Solid Tumors.